| Name | MS023 dihydrochloride |
| Description | MS023 dihydrochloride (MS023 2HCl) is a selective, cytosolic and highly potent inhibitor of human type I protein arginine methyltransferases (PRMTs) with antitumour activity, inhibits PRMT1, PRMT3, PRMT4, PRMT6, and PRMT8, and increases the proliferative capacity of isolated cultured MuSC. It can be used to study breast cancer. |
| In vitro | MS023 dihydrochloride (1-1000 nM) effectively and concentration-dependently reduces PRMT1 methyltransferase activity in MCF7 cells[1]. |
| In vivo | In NOD-scid IL2Rgnull (NSG) mice bearing primary MLL-r ALL cells, combinatorial treatment with MS023 dihydrochloride (160 mg/kg, ip) and PKC412 (100 mg/kg, i.g.) for 4 weeks extended the survival of leukemic mice compared to single treatments[2]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : 20 mg/mL (55.51 mM), Sonication is recommended. DMSO : 100 mg/mL (277.53 mM), Sonication is recommended.
|
| Keywords | PRMT8 | PRMT6 | PRMT4 | PRMT3 | PRMT1 | HistoneMethyltransferase | Histone Methyltransferase |
| Inhibitors Related | MAK-683 hydrochloride | SNDX-5613 | Tazemetostat | Piribedil | XY1 | UNC 0631 | (Iso)-Flavokawain A | EPZ015666 | iso-Azalansta | AMI-1 free acid | MS37452 | MRTX-1719 |
| Related Compound Libraries | Histone Modification Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Epigenetics Compound Library | Anti-Breast Cancer Compound Library | Multi-Target Compound Library | Post-Translational Modification Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library | High-Efficiency Gene Editing Small Molecule Library |